scholarly journals Changes in tumor oxygen state after sorafenib therapy evaluated by 18F-fluoromisonidazole hypoxia imaging of renal cell carcinoma xenografts

2017 ◽  
Vol 14 (2) ◽  
pp. 2341-2346 ◽  
Author(s):  
Wenwen Yu ◽  
Songji Zhao ◽  
Yan Zhao ◽  
Chowdhury Nusrat Fatema ◽  
Masahiro Murakami ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Hypoxia Imaging ◽  
Sorafenib Therapy ◽  
Oxygen State

scholarly journals Pilot study of DCE-MRI to predict progression-free survival with sorafenib therapy in renal cell carcinoma

2008 ◽  
Vol 7 (4) ◽  
pp. 496-501 ◽  
Author(s):  
Keith T. Flaherty ◽  
Mark A. Rosen ◽  
Daniel F. Heitjan ◽  
Maryann L. Gallagher ◽  
Brian Schwartz ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Pilot Study ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Progression Free Survival ◽  
Free Survival ◽  
Dce Mri ◽  
Sorafenib Therapy

Activity of retreatment with sorafenib for metastatic renal cell carcinoma.

2011 ◽  
Vol 29 (7_suppl) ◽  
pp. 404-404 ◽  
Author(s):  
M. Nozawa ◽  
N. Matsumura ◽  
M. Yasuda ◽  
Y. Okuda ◽  
H. Uemura
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Metastatic Renal Cell Carcinoma ◽  
Clinical Benefit ◽  
Renal Cell ◽  
Objective Response ◽  
Interleukin 2 ◽  
Severe Toxicity ◽  
Sorafenib Therapy ◽  
Significant Difference

404 Background: Treatment options for metastatic renal cell carcinoma (mRCC) have increased. Complete remission is, however, rarely seen and patients are treated with multiple sequential therapies. We assessed clinical activity of sorafenib rechallenge after progressing on other therapies. Methods: Patients with mRCC who received a second course of sorafenib therapy after failure of prior sorafenib and other agents were retrospectively identified. RECIST-defined objective response rate and progression-free survival (PFS) and toxicity were analyzed. Results: Fourteen patients with mRCC who were retreated with sorafenib were identified and twelve patients were assessable for this study. 92% were male. Median age at first systemic therapy was 63 years. Prior nephrectomy was performed in 92% of patients. 42% of patients had favorable or intermediate risk, 17% poor, and the rest not available per MSKCC criteria. Eighty-three percent of patients were treated with other agents before initial sorafenib therapy, including 75% interferon-alpha (IFN-alpha), 50% interleukin-2 (IL-2), and 17% sunitinib. First sorafenib therapy began a median of 9.0 months after the diagnosis of mRCC and produced a clinical benefit (PR + SD) rate of 75% and a median PFS of 5.0 months. 67% of patients discontinued initial sorafenib for disease progression and 33% for adverse events. Interval between discontinuation of initial sorafenib and rechallenge was a median of 7.6 months. During the intervening period, 50% of patients were treated with sunitinib, 33% with everolimus, 25% with VEGFR1 vaccine, and others. Clinical benefit rate of 67% and a median PFS of 4.3 months were obtained on sorafenib rechallenge. There was no significant difference in outcome to sorafenib rechallenge based on duration between sorafenib treatments or number or type of intervening treatments. No new severe toxicity was observed during rechallenge. Conclusions: Sorafenib rechallenge has potential to achieve clinical benefits, is well-tolerated, and may be considered after multiple sequential therapies in select mRCC patients. No significant financial relationships to disclose.

scholarly journals Treatment of adult rhabdoid renal cell carcinoma with sorafenib

2008 ◽  
Vol 2 (6) ◽  
pp. 631 ◽  
Author(s):  
Anil Kapoor ◽  
Robert Tutino ◽  
Androniki Kanaroglou ◽  
Sebastien J. Hotte
Keyword(s):  
Renal Cell Carcinoma ◽  
Tyrosine Kinase Inhibitor ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Kinase Inhibitor ◽  
Clear Cell ◽  
Review Of The Literature ◽  
Histological Findings ◽  
Sorafenib Therapy ◽  
Rhabdoid Features

Renal cell carcinoma (RCC) with rhabdoid features is an uncommon and highly aggressive malignancy. We report a case of adult clear-cell RCC with extensive rhabdoid features treated with the tyrosine kinase inhibitor sorafenib. A review of the literature summarizes important aspects of this malignancy. We discuss clinical and histological findings as well as the patient’s response to sorafenib therapy.

scholarly journals Metastatic renal cell carcinoma kidney in children 10 years old – possibility of targeted therapy

2018 ◽  
Vol 13 (4) ◽  
pp. 126-132
Author(s):  
A. Yu. Pavlov ◽  
Z. R. Sabirzyanova ◽  
O. G. Zheludkova ◽  
A. V. Mikhalchenko
Keyword(s):  
Renal Cell Carcinoma ◽  
Targeted Therapy ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Clinical Observation ◽  
Radical Surgery ◽  
Treatment Protocol ◽  
Progression Free Survival ◽  
Free Survival ◽  
Sorafenib Therapy

Renal cell carcinoma (RCC) is rare in children, its metastatic form is even rarer. At present there is no treatment protocol for children with RCC. This clinical observation presented the patient 10 year old with RCC metastases to the lungs. After radical surgery, after targeted sorafenib therapy the patient has a positive dynamics. At present his progression-free survival is 30 months.

Sign in / Sign up

Export Citation Format

Share Document